供者调节性T细胞输注联合低剂量白细胞介素-2治疗激素难治性慢性移植物抗宿主病的1期研究
这项1期研究在25例激素难治性慢性移植物抗宿主病(SR-cGVHD)成人患者中,联合输注供者来源调节性T细胞(Treg DLI,起始0.1×10^6 cells/kg,最高1×10^6 cells/kg)与低剂量白细胞介素-2(1×10^6 IU/m2/日,共8周)。治疗耐受良好,8周时5/25例(20%)达部分缓解,另10例(40%)疾病稳定伴未达部分缓解标准的轻微缓解;Treg克隆选择性扩增并长期存续。
要点
- 供者Treg输注联合低剂量IL-2在SR-cGVHD中耐受良好,8周部分缓解率为20%(5/25)。
- 另40%(10/25)患者疾病稳定伴未达部分缓解标准的轻微缓解。
- 各剂量水平Treg扩增相似,CD4+常规T细胞与CD8+ T细胞无显著变化。
核心结论
- 首次证明输注多克隆健康供者Treg后以低剂量IL-2扩增在SR-cGVHD患者中是安全的,为移植后过继性Treg治疗奠定基础。
研究设计与样本
- 1期研究,纳入25例激素难治性慢性移植物抗宿主病成人患者,联合单次供者Treg富集淋巴细胞输注(Treg DLI)与低剂量IL-2(1×10^6 IU/m2/日,共8周),Treg未在体外扩增。
- Treg DLI起始剂量为0.1×10^6 cells/kg患者,递增至最大剂量1×10^6 cells/kg。
- 试验注册号NCT01937468。
主要发现
- 治疗8周后,25例中5例(20%)达部分缓解(PR)。
- 另10例(40%)疾病稳定伴未达PR标准的轻微缓解。
- 各剂量水平患者Treg扩增相似,CD4+常规T细胞或CD8+ T细胞无显著变化。
- T细胞受体β位点高通量测序显示Treg多样性选择性改善。
- 部分DLI来源Treg克隆在第8周优先扩增,并在输注后1年长期存续。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic graft-versus-host disease (cGVHD) remains a frequent cause of nonrelapse morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Despite recent advances, options for steroid-refractory (SR) cGVHD are limited. In previous trials of low-dose interleukin-2 (LD IL-2), the immunomodulatory properties of regulatory T cells (Tregs) have been harnessed to treat SR-cGVHD safely and effectively. In the present study, we combined a single infusion of Treg-enriched lymphocytes (Treg DLI) from the original stem cell donor with in vivo Treg expansion using LD IL-2 (1 × 106 IU/m2 per day for 8 weeks) in 25 adult patients with SR-cGVHD. Treg were not expanded ex vivo. Treg DLI was initiated at 0.1 × 106 cells per kg patient and escalated to a maximum dose of 1 × 106 cells per kg. Treg DLI plus LD IL-2 was well tolerated and led to partial responses (PR) in 5 of 25 patients (20%) after 8 weeks of therapy. Ten additional patients (40%) had stable disease with minor responses not meeting PR criteria. Patients at all dose levels had similar Treg expansion without significant changes in CD4+ conventional T cells or CD8+ T cells. High-throughput sequencing of the T-cell receptor β locus showed selective improvement of Treg diversity. A subset of DLI-derived Treg clones showed preferential expansion at week 8 and long-term persistence 1-year postinfusion. We demonstrate for the first time that infusion of polyclonal healthy donor Tregs followed by expansion with LD IL-2 is safe in patients with SR-cGVHD, thus establishing a foundation for future adoptive Treg therapies in the posttransplant setting. This trial was registered at www.clinicaltrials.gov as #NCT01937468.
引用
- Whangbo JS, Nikiforow S, Kim HT, et al. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022. PMID: 35475885. doi:10.1182/bloodadvances.2021006625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。